Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 8/20 | 0.57 |
| ▸ | TYMS | P04818 | 6/20 | 0.57 |
| ▸ | GART | P22102 | 3/20 | 0.57 |
| ▸ | ATIC | P31939 | 2/20 | 0.57 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.57 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.57 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.57 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.57 |
| ▸ | FRK | P42685 | 1/20 | 0.57 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27835031 | 1.00 | DHFR (0.57) | DHFRTYMSGARTATICFOLR2 | |
| SCHEMBL207059 | 0.92 | TYMS (0.50) | DHFRTYMSGARTATICFOLR2 | |
| SCHEMBL13003773 | 0.92 | GART (0.51) | DHFRTYMSGARTATICFOLR2 | |
| SCHEMBL12370806 | 0.91 | DHFR (0.50) | DHFRTYMSGARTATICFOLR2 | |
| SCHEMBL1236538 | 0.90 | TYMS (0.56) | DHFRTYMSGARTATICFOLR2 | |
| SCHEMBL19623246 | 0.90 | TYMS (0.56) | DHFRTYMSGARTATICFOLR2 | |
| SCHEMBL7844331 | 0.89 | TYMS (0.72) | DHFRTYMSGARTATICFOLR2 | |
| SCHEMBL15078818 | 0.89 | TYMS (0.72) | DHFRTYMSGARTATICFOLR2 | |
| SCHEMBL7844327 | 0.89 | TYMS (0.72) | DHFRTYMSGARTATICFOLR2 | |
| SCHEMBL2756063 | 0.88 | DHFR (0.48) | DHFRTYMSGARTATICFOLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017168442-A1 | NOVEL STABLE SALTS OF PEMETREXED | SHAH DHARMESH MAHENDRABHAI (IN) | 2017-10-05 | — | — | WO | claimed |
| WO-2017168442-A1 | NOVEL STABLE SALTS OF PEMETREXED | SHAH DHARMESH MAHENDRABHAI (IN) | 2017-10-05 | — | — | WO | disclosed |
| US-9718829-B2 | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | SICOR INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170129900-A1 | Crystalline Forms Of Pemetrexed Diacid And Processes For The Preparation Thereof | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2017-05-11 | — | — | US | disclosed |
| US-9562050-B2 | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | SICOR, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9156841-B2 | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | SICOR INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2409978-B1 | A novel process for the synthesis of pemetrexed disodium salt | CHEMI SPA (IT) | 2013-09-11 | — | — | EP | disclosed |
| EP-2409978-A2 | A novel process for the synthesis of pemetrexed disodium salt | Chemi SPA (IT) | 2012-01-25 | — | — | EP | disclosed |
| US-8088919-B2 | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | SICOR INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20080045711-A1 | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2008-02-21 | — | — | US | disclosed |
| EP-0905128-B1 | Processes and intermediates useful to make antifolates | LILLY CO ELI (US) | 2002-02-20 | — | — | EP | disclosed |
| US-20010011142-A1 | Processes and intermediates useful to make antifolates | KJELL DOUGLAS PATTON (US) | 2001-08-02 | — | — | US | disclosed |
| US-6262262-B1 | PRODUCING 4-(2-(2-AMINO-4,7-DIHYDRO-4-OXO-1H-PYRROLO(2, 3-D)PYRIMIDIN-5-YL)ETHYL)BENZOIC ACID DERIVATIVE BY REACTING HYDROXY-4-(4-CARBOMETHOXYPHENYL)BUTANESULFONIC ACID METAL SALT WITH TRIALKYLSILYL HALIDE; REACTING WITH | ELI LILLY AND COMPANY | 2001-07-17 | — | — | US | disclosed |
| EP-0905128-A1 | Processes and intermediates useful to make antifolates | ELI LILLY AND COMPANY (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5663339-A | Process for preparing 5-substituted pyrrolo-[2,3-D] pyrimidines | ELI LILLY AND COMPANY (US) | 1997-09-02 | — | — | US | disclosed |
| US-5644058-A | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines | ELI LILLY AND COMPANY (US) | 1997-07-01 | — | — | US | disclosed |
| US-5612482-A | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines | ELI LILLY AND COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5416211-A | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines | ELI LILLY AND COMPANY (US) | 1995-05-16 | — | — | US | disclosed |
| EP-0589720-A2 | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines | ELI LILLY AND COMPANY (US) | 1994-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045711-A1 | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | DCTD, DPYD, TYMP | DHFR 6/4885TYMS 9/4885GART 37/4885 |
| US-20170129900-A1 | Crystalline Forms Of Pemetrexed Diacid And Processes For The Preparation Thereof | DCTD, DPYD, DHFR | DHFR 3/4885TYMS 7/4885GART 34/4885 |
| US-20010011142-A1 | Processes and intermediates useful to make antifolates | DPYD, DHFR, MPST | DHFR 2/4885TYMS 10/4885GART 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.